Ondine Biomedical, Inc.(GB:OBI)
GBX 8.650.00 (0.00%)
GB:OBI
Ondine Biomedical, Inc. stock drug pipeline
GBX 8.65
At close:0.00 (0.00%)
Want to see GB:OBI full AI Analyst Report?
Ondine Biomedical, Inc. (OBI) Drug Pipeline
16 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Nasal Antimicrobial Photodisinfection Therapy | Anti-Infective Agents, Infections, Surgical Site Infections, Surgical Wound Infection | Phase III | Recruiting | Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections | Nov 12, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Nasal Antimicrobial Photodisinfection Therapy | Phase III | Anti-Infective Agents, Infections, Surgical Site Infections, Surgical Wound Infection | Recruiting | Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections | Nov 12, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ondine Biomedical, Inc. (GB:OBI) have in its pipeline
Ondine Biomedical, Inc. GB:OBI is currently developing the following drugs: Nasal Antimicrobial Photodisinfection Therapy. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

